Celularity Return on Equity

Celularity's return on equity stands at 240.96%. That is above the Healthcare sector average of 21.28%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Celularity sits higher the Healthcare benchmark (21.28%) with a ROE of 240.96%. That is roughly 1032.3% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of 240.96% for Celularity means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Celularity's ROE evolved across reporting periods, while the comparison chart places CELU next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, ROE is commonly used to spot outliers. Celularity's reading of 240.96% (sector avg 21.28%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.